Pernix Therapeutics Holdings (Nasdaq: PTX ) reported earnings on March 18. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Pernix Therapeutics Holdings whiffed on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue contracted. Non-GAAP earnings per share shrank to a loss. GAAP earnings per share dropped to a loss.
Margins dropped across the board.
Pernix Therapeutics Holdings reported revenue of $18.2 million. The six analysts polled by S&P Capital IQ expected a top line of $23.4 million on the same basis. GAAP reported sales were 15% lower than the prior-year quarter's $21.4 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.03. The six earnings estimates compiled by S&P Capital IQ anticipated $0.03 per share. Non-GAAP EPS were -$0.03 for Q4 versus $0.16 per share for the prior-year quarter. GAAP EPS were -$0.05 for Q4 compared to $0.14 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 58.7%, much worse than the prior-year quarter. Operating margin was -8.6%, much worse than the prior-year quarter. Net margin was -7.7%, much worse than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $28.3 million. On the bottom line, the average EPS estimate is -$0.05.
Next year's average estimate for revenue is $119.7 million. The average EPS estimate is -$0.11.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Pernix Therapeutics Holdings is outperform, with an average price target of $12.40.
- Add Pernix Therapeutics Holdings to My Watchlist.